1. Home
  2. WHWK vs NTHI Comparison

WHWK vs NTHI Comparison

Compare WHWK & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

196.3M

Sector

Health Care

ML Signal

HOLD

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$4.10

Market Cap

178.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHWK
NTHI
Founded
2007
2008
Country
United States
United States
Employees
23
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.3M
178.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WHWK
NTHI
Price
$3.98
$4.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.50
$15.00
AVG Volume (30 Days)
203.6K
61.3K
Earning Date
05-06-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$3.20
52 Week High
$4.40
$12.99

Technical Indicators

Market Signals
Indicator
WHWK
NTHI
Relative Strength Index (RSI) 54.71 23.10
Support Level $1.84 $4.00
Resistance Level $4.40 $5.82
Average True Range (ATR) 0.29 0.49
MACD -0.02 0.03
Stochastic Oscillator 59.18 9.78

Price Performance

Historical Comparison
WHWK
NTHI

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Share on Social Networks: